This trial is testing whether a new immunotherapy treatment, using a patient's own immune cells, can be successful in treating adults with leukemia or lymphoma that has returned or does not respond to treatment.
- Non-Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia (ALL)
- Follicular Lymphoma, Grade 3b
3 Primary · 2 Secondary · Reporting Duration: 28 days after infusion of CD22 CAR T cells
2 Treatment Groups
1 of 2
R/R aggressive B-cell NHL
1 of 2
92 Total Participants · 2 Treatment Groups
Primary Treatment: CD22 CAR · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 29 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Baird, John H., Matthew J. Frank, Juliana Craig, Shabnum Patel, Jay Y. Spiegel, Bita Sahaf, Jean S. Oak, et al.. 2021. “Cd22-directed CAR T-cell Therapy Induces Complete Remissions in Cd19-directed Car–refractory Large B-cell Lymphoma”. Blood. American Society of Hematology. doi:10.1182/blood.2020009432.
- 2019. "Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04088890.
Frequently Asked Questions
What is the primary purpose of administering CD22 CAR treatments?
"CAR-CD22 has been proven to work as an efficacious treatment for multiple sclerosis. Additionally, it is beneficial in managing cases of mixed-cell type lymphoma, leukemia, myelocytic and acute types of retinoblastoma." - Anonymous Online Contributor
What prior experiments have been conducted involving CD22 CAR technology?
"889 clinical trials relating to CD22 CAR are currently operational with 161 of these studies being conducted in phase 3. The majority of the research is concentrated around Philadelphia, Pennsylvania but there are 28443 sites worldwide conducting similar experiments." - Anonymous Online Contributor
Are there vacancies available to prospective participants of this clinical trial?
"According to clinicaltrials.gov, the research is in its recruitment stage. This trial was initially posted on September 12th 2019 and has been updated most recently on January 14th 2022." - Anonymous Online Contributor
How many individuals are currently participating in this research initiative?
"Affirmative. According to the clinicaltrials.gov database, this particular research is actively seeking participants; first posted on September 12th 2019 and last updated January 14th 2022. The study requires enrolment of 92 patients from a single medical centre." - Anonymous Online Contributor
Has the application for CD22 chimeric antigen receptor therapy been sanctioned by the Food and Drug Administration?
"Due to the experimental nature of this medical research, CD22 CAR has been rated a 1 on our safety scale. This is because Phase 1 trials provide limited evidence for efficacy and safety." - Anonymous Online Contributor